What: Investors in the clinical-stage bio Ophthotech (NASDAQ:OPHT) have had to deal with a brutal start to the year. Shares are currently down more than 31% since the calendar turned to 2016, according to data from S&P Global Market Intelligence.
So what: So why has the market soured on the company's shares? Here's a review of a few key developments that have caused Ophthotech's stock to move this year.
- In January, Ophthotech announced that it had dosed its first patient with Zimura. This phase 2/3 study is testing the experimental compound's ability to treat geographic atrophy, which is a common advanced form of dry age-related macular degeneration (AMD). An estimated 8 million people suffer from vision loss related to this condition, and there are no approved treatment options, so this is a big opportunity for the company. Still, despite the good clinical progress, shares tumbled 31% during the month.
- Shares dropped again in March after SEC filings showed that key members of the company's management team unloaded a sizable number of shares.
- In June, the company announced that it had completed enrollment in a phase 3 trial evaluating Fovista's use in combination with either Eylea or Avastin as a treatment for wet AMD. This triggered a $30 million milestone payment from the company's partner, Novartis.
Since the news has almost universally been positive out of the company, I have a hard time believing that shares have plunged because of a few insider sales. What's far more likely is that the company's stock has simply been a victim of the general biotech sell-off.
Take a look at the year-to-date performance of the SPDR S&P Biotech ETF (NYSEMKT:XBI) compared with Ophthotech's stock to see what I mean.
Now what: Shares of Ophthotech may be in the doghouse in 2016, but a little perspective is warranted. Keep in mind that Ophthotech soared 75% higher in 2015, so perhaps it's unsurprising to see traders in profit-taking mode, given that there's so much fear surrounding any clinical-stage biotech right now.
Despite the poor performance, I continue to see plenty of reasons to be optimistic about Ophthotech's future. Remember that clinical trials showed that using the company's experimental drug Fovista alongside Novartis' Lucentis showed a 10.6-letter improvement in vision on a standard eye chart. That result compares favorably with the 6.5-letter improvement among patients who used Lucentis alone. It's possible that clinical results could show a similar improvement when we see data from the Eylea/Avastin trials, too. If so, then Fovista holds real promise to become a standard-of-care treatment in a fast-growing, multibillion-dollar market.
Add that to the potential Zimura holds, and it's not hard to believe that Ophthotech could start to turn a profit in just a few years' time. In fact, at least one analyst is predicting that the company will be earning more than $7 per share by 2020. If that prediction proves even close to matching reality, then shares look to be very attractively priced today. Investors with a stronger-than-average stomach for risk might want to consider adding a few shares of this promising stock to their portfolio.